Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being Studied To Prevent Acute Kidney Injury In High-Risk Patients Undergoing Cardiac Surgery

Loading news article.

Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being Studied To Prevent Acute Kidney Injury In High-Risk Patients Undergoing Cardiac Surgery | WAPE

Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being Studied To Prevent Acute Kidney Injury In High-Risk Patients Undergoing Cardiac Surgery

Article summary

Related companies

Comments —